Susan Haigney

FDA, Approved Food and Drug Administration concept. Quality, certification, health product standards control system. Businessman manages pharmaceutical quality documents. | Image Credit: ©Pakin -stock.adobe.com

FDA has officially launched its PreCheck Pilot Program, which is designed to bolster the domestic pharmaceutical supply chain by streamlining the regulatory assessment process for manufacturing facilities based in the United States.

 By providing enhanced regulatory predictability and early engagement, the program aims to facilitate the construction of domestic sites and expedite the evaluation of manufacturing elements before a specific product application is even filed.

Is this a strategic shift toward onshoring?

FDA Commissioner Marty Makary, M.D., M.P.H., characterized the program as a “bold step” to bring manufacturing back to the US and make the domestic sector more resilient and competitive. This program is positioned as one of several incentives the agency is deploying to strengthen the nation's drug supply.

“After 35 years of globalists taking pharmaceutical manufacturing overseas, the FDA is taking bold steps to bring it back," said FDA Commissioner Marty Makary, M.D., M.P.H, in the press release.

 “The PreCheck program is one of several powerful incentives we are providing to make the US pharmaceutical manufacturing sector more resilient and competitive.”

The PreCheck program is structured into two distinct phases to ensure comprehensive support throughout the facility development lifecycle (see 

The agency will begin conducting PreCheck activities with an initial cohort of new facilities in 2026. Selection for the program is competitive and based on alignment with national priorities.

FDA will evaluate applicants based on the following criteria:

 Facilities producing critical medications for the US market will receive priority consideration.

 The current phase of facility development and the projected timeline for reaching the US market.

 A focus on innovative approaches to facility development and manufacturing processes.

The design of PreCheck is not a top-down mandate but a reflection of extensive industry collaboration, according to the agency. FDA incorporated feedback from a public meeting held on Sept. 30, 2025, titled “Onshoring Manufacturing of Drugs and Biological Products”. Industry stakeholders expressed strong support for early engagement during facility development and the implementation of streamlined documentation processes, both of which are now core components of the PreCheck model.

Onshoring efforts may be driven by a need to mitigate the risks associated with global logistics and “just-in-time” supply chains. Companies wishing to establish new API manufacturing facilities may face regulatory roadblocks including inspection predictability and post-approval flexibility.

Manufacturers interested in participating in the 2026 program should review the eligibility and selection criteria on the official 

. The agency is currently accepting requests to participate as of Feb. 1, 2026.

FDA. FDA Launches PreCheck Pilot Program to Strengthen Domestic Pharmaceutical Manufacturing. Press release. Feb. 1, 2026. 

https://www.fda.gov/news-events/press-announcements/fda-launches-precheck-pilot-program-strengthen-domestic-pharmaceutical-manufacturing

Schwartz, M.I. and Kim, J. Onshoring Drug Manufacturing. Insights from FDA’s PreCheck Initiative and Public Meeting. TheFDALawBlog.com. Oct. 28, 2025. 

https://www.thefdalawblog.com/2025/10/onshoring-drug-manufacturing-insights-from-fdas-precheck-initiative-and-public-meeting

Articles

The FDA has introduced the PreCheck pilot program to enhance the U.S. pharmaceutical supply chain by streamlining regulatory assessments for domestic manufacturing facilities. This initiative aims to encourage onshoring by providing regulatory predictability and early engagement, thus expediting facility development and evaluation. The program, structured in two phases, will begin with a cohort of new facilities in 2026, selected based on criteria like product type, development stage, and innovation. Industry feedback played a crucial role in shaping the program, emphasizing early engagement and streamlined documentation.

The PreCheck Pilot Program is designed to strengthen the US pharmaceutical supply chain by increasing regulatory predictability and streamlining the assessment of new domestic manufacturing sites.

FDA Launches PreCheck Pilot Program to Bolster Domestic Drug Manufacturing

International Day of Women and Girls in Science

, Technical Team leader, Symbiosis Pharmaceutical Services Ltd., about her achievements working in the pharmaceutical industry and her opinions on the roles women play in science, technology, engineering, and mathematics (STEM) fields, especially when it comes to innovation in drug development.

What can you tell us about your background and your career in STEM?

 I’m originally from South Uist, an island off the coast of Scotland, where access to STEM careers is limited, but I grew up with a keen interest for science; and I was able to achieve a Master’s in Chemistry and Drug Discovery from Strathclyde University. I spent my Master’s placement year working at Pfizer in Cork, Ireland where I was first exposed to pharmaceutical manufacturing, where I have found my interest lies and where I felt best suited my strengths in problem solving.

After graduating with my Master’s degree, I moved back to Cork to work for Eli Lilly, where I had fantastic mentorship from women in leadership roles. Seeing women in leadership increased my drive for success as I felt achieving my goals was more realistic. During this time, under the mentorship of my colleagues, I developed networks and relationships, which have contributed to my success.

After COVID I took around eight months off to travel around Southeast Asia and Australia. This was a fantastic experience where I was able to meet a diverse spectrum of people and get a new perspective on life.

While living in Australia, I worked for CSL Seqirus, where I obtained experience in the validation side of pharmaceutical manufacturing. One of the things that drew me to CSL as a company was that over 50% of their workforce was women, which is rare in STEM. This showed the company’s commitment to ensuring women in STEM have access to opportunities to allow us to succeed.

Since moving back to Scotland, I have been working at Symbiosis. We have a fantastic team here, and it has been a pleasure working with everyone. Symbiosis also has a diverse leadership team with representation of women within STEM. I am looking forward to continuing my career here.

What are some of the benefits of STEM programs for girls in school? How do these programs translate to women building careers in the pharmaceutical industry?

 STEM programs in schools are necessary for visibility of the diversity of career paths and visibility of what women can achieve in their careers in the pharmaceutical manufacturing industry. I was not aware until my placement year at university of all the essential roles involved in making a pharmaceutical manufacturing plant effective and there’s something for every type of person including roles in operations, quality assurance, engineering, quality control, process development, health and safety, supply chain logistics, project and construction management, the list goes on! If we have visibility from an early age of the types of roles that are available in the pharmaceutical industry, it will make us as women more likely to engage with STEM courses at university as an entry point.

Financial support such as university grants, paid placements/internships and industry mentorship programmes are ways in which we can encourage women to consider STEM careers.

It’s within pharmaceutical manufacturing that research is realized to manufacture medicines. The challenges we face when ensuring a safe product for patients and a safe process for manufacturing are engaging ways of putting the critical thinking skills developed in STEM programs into practise.

It is important that women working in the pharmaceutical industry encourage young women to explore their interest in science. It can seem a daunting prospect to enter a career in a typically male-dominated industry so support networks for women within the workplace and between industry and universities are essential to bridge the gap for young women entering careers in pharmaceutical manufacturing. I personally had a fantastic network of supportive female mentors while working in previous roles whose guidance has shaped my career so far.

How do women working in STEM fields uniquely contribute to areas such as rare disease treatment development?

 Science is for everyone, and women in STEM can uniquely contribute their individual ways of thinking to improve areas such as rare disease development.

Women in STEM have made fantastic contributions to areas like rare disease treatment, such as Dr. Caroline Barelle who founded 

, which is working to innovate immune mediated diseases.

What exciting innovations do you see on the horizon for the pharmaceutical industry?

I am always interested in process analytics, as my introduction to pharmaceutical manufacturing was in the Pfizer manufacturing process analytics and control department. Advancements in the analysis of process data used to determine root causes for process issues or to highlight out of trend data before an issue occurs will always be beneficial in the pharmaceutical manufacturing industry.

Another subject I have been finding interesting lately is AI and machine learning in drug discovery. Drug discovery is typically a long process spanning a decade or more; however with advancements in AI to streamline this pathway, assist in improving lead target identification and the potential for safer drugs evaluating existing data, this may reduce critical timelines to bringing a drug to clinic.

Who are you inspired by in the pharmaceutical industry

 On a personal level, I am inspired everyday by the women I work with. I have had some fantastic female mentors who have supported me professionally and personally throughout my career to date. The support of female mentors has helped me to decide which direction I would like my career to progress in and having visibility of women in leadership positions inspires hope for my future.

I attended a conference recently where I had the pleasure of meeting Dr. Catherine Green; her passion for vaccine development was inspiring. Her story about how the Oxford AstraZeneca COVID-19 vaccine was developed in such a short timeline was an exciting example of the pace pharmaceutical development and manufacturing can move at in a time of need and her contribution ultimately saved countless lives throughout the COVID pandemic. This especially hit close to home with my role at Symbiosis, as the company played a pivotal role in the clinical development of the Oxford AstraZeneca vaccine, manufacturing nearly one million doses to support clinical trials and enable accelerated regulatory approval in the United Kingdom.

What are you currently working on that you are passionate about?

 Symbiosis has recently opened a new manufacturing facility in Stirling, increasing our manufacturing capacity up to 15,000 vials per batch. This additional capacity will allow the company to build long-lasting partnerships with clients as they move from the clinical trials stage to commercial manufacturing.

I am immensely proud of the Symbiosis team for the hard work and commitment that has gone into getting the facility operational. This has been an exciting project to be part of, and the passion in our team for ensuring manufacturing in this facility will be successful has been inspiring.

UN. International Day of Women and Girls in Science, 11 February. UN.org. 

https://www.un.org/en/observances/women-and-girls-in-science-day

Katy MacLellan, Technical Team leader, Symbiosis Pharmaceutical Services

Katy MacLellan is Technical Team leader at Symbiosis Pharmaceutical Services. Symbiosis is a contract development and manufacturing organization based in Stirling, Scotland, specialising in the good manufacturing practice sterile manufacturing of injectable drug products. MacLellan works on tech transfers for client projects.



Katy MacLellan, a Technical Team Leader at Symbiosis Pharmaceutical Services, shares her journey in the pharmaceutical industry, emphasizing the importance of women in STEM fields. She highlights the role of STEM programs in schools for career visibility and the need for financial support and mentorship to encourage women in STEM. MacLellan discusses the unique contributions women make in areas like rare disease treatment and the potential of AI in drug discovery. She is inspired by female mentors and is passionate about expanding Symbiosis's manufacturing capabilities.

PharmTech spoke with Katy MacLellan, Technical Team leader, Symbiosis Pharmaceutical Services Ltd., about the women in the pharmaceutical industry that inspire her.

Women in STEM: Inspiration from Innovators in Pharma

In a 2026 industry outlook interview, Raj Puri explains balancing speed with the financial and regulatory risks of accelerated drug launches via alignment.

Navigating the Complex Risks of Accelerated Pharmaceutical Launches

Raj Puri, chief commercial officer at Argonaut Manufacturing, explores the complex balance between speed and risk in pharmaceutical product launches. Puri explains that while getting a product to market quickly is vital for patient access and commercial survival, compressed timelines introduce significant regulatory and financial hurdles. He notes that, "As a biotech or pharma company, getting product to market as quickly as possible is critical”.

One of the primary challenges discussed is the "gamble" of mass production. Puri highlights that accelerated timelines often force companies to decide whether to manufacture commercial-scale products before receiving indicative guidance from regulatory agencies. He explains, "The compressed review timeline actually forces the biotech and pharma companies into taking a bit of a gamble, and that decision really is, do you start mass production before you have indicative regulatory feedback?". This financial risk is compounded by the need to negotiate proactively with agencies for allowances, such as submitting manufacturing data on a rolling basis.

Puri also shares a personal case study involving a life-saving biologic where the Phase 3 study was discontinued early due to "overwhelming efficacy". While a positive outcome, this created a gap in patient access during the submission window and led to clinical utilization challenges. Because the study ended early, the resulting regulatory label required ICU clinicians to use unfamiliar clinical trial tools, necessitating a massive educational effort.

Finally, the interview addresses the global implications of accelerated launches. Different requirements from the FDA, EMA, and Japanese Health Authorities often force companies to prioritize one jurisdiction over others. Puri concludes that while compressed timelines are highly desirable, they necessitate robust contingency strategies and a deep, collaborative relationship with regulatory bodies to ensure alignment on all requirements.

Editor's note: This transcript is a lightly edited rendering of the original audio/video content. It may contain errors, informal language, or omissions as spoken in the original recording.

Good morning. My name is Raj Puri. I'm the Chief Commercial Officer at Argonaut manufacturing. Argonaut is a contract manufacturing company based in Carlsbad, California. We have two separate divisions within the company. One division is focused on the production of life science and diagnostic products, and then the second division is focused on aseptic filling of drug product. So again, pleasure to be here today.

As a biotech or pharma company, getting product to market as quickly as possible is critical. Both from a patient access perspective, you want to save or improve lives of many patients as possible, as quickly as possible, but also from a commercial perspective, we basically burn cash until we get to market. So, from a commercial perspective, getting there as quickly as possible is obviously desirable. It can have significant challenges, these compressed timelines, and I've gone through them, personally, myself, from a regulatory perspective, what you can often see is that you're able to negotiate proactively with the agencies allowances regarding the data required on submission. And so again, you have to work very closely with the agency to determine what allowances will be made. But for example, in your PPQ package, which is essentially the manufacturing data that's provided on your submission, you may have the opportunity to reduce the amount of data provided and provided on a rolling basis, rather than everything has to go in at once on the submission date. So again, it takes close coordination with the regulatory body to negotiate those allowances.



From a commercial risk perspective, the compressed review timeline actually forces the biotech and pharma companies into taking a bit of a gamble, and that decision really is, do you start mass production before you have indicative regulatory feedback? So typically, let's say you have a year review timeline. After six months, you probably have some guidance whether or not your clinical package is acceptable or not. You then can say, after six months, everything looks good, we're going to pull the trigger. There's some risk here. But, clinical data looks pretty good. We're going to make the decision to manufacture and have product ready for launch. When you have a compressed timeline, you can't actually make that decision. You may actually have to make a decision on actual submission before you have any indicative guidance about whether or not you're going to make product to be ready for commercial launch. So there's a significant financial risk associated with making that decision at the time of submission versus when you have some indicative guidance from the agency. Personally, early in my career, I was part of a team at one of the big pharma companies responsible for setting regulatory strategy for a lifesaving biologic. The phase three study was actually discontinued due to overwhelming efficacy, which again, was a fantastic outcome. We were very, very excited the product was saving lives, and it became not ethical now to treat patients with a placebo when we knew that the active was extremely effective.

So we're very excited, but it did create some significant challenges for us on the back end. So, one of those challenges was actually a patient access issue. We discontinued study due to overwhelming efficacy, and it took us probably six to eight months to actually make a submission to the regulatory agency. You have to compile all the data, do the analysis, and then you have a review time on top of that. We did not have a scalable program in place where we continue to have availability for patients to access this product. So that was a major challenge from a patient access perspective, in that window between study discontinuation and commercial approval. And then from a clinical utilization perspective, we also had a challenge in that, because the study was discontinued early, we had a much smaller patient population than we had anticipated. What ended up happening was that the regulatory agencies then integrated into our label, the use of a clinical trial severity score.

What that meant is that you now had, commercially, you had clinicians that weren't involved in clinical trials were being asked to use a tool that they never used before. And so from a commercial perspective, we're now trying to educate the ICU doctors and nurses on how to actually assess patients effectively using this tool. And it's something they'd never done before. And so that also created a major challenge for us, again, somewhat precipitated by the compressed timeline. At the end of the day, the compressed outlines, while extremely desirable, they really do force companies to have a very robust contingency strategy developed prior to submission, and really forces them to work very closely with the regulatory agencies to make sure that they have alignment regarding requirements. It also may have the unintended effect of forcing companies to prioritize certain jurisdictions over others. Because, what the FDA may require might be quite different than what the EMA require, which may be different than what the Japanese Health Authority requires. And so now you have to say, Okay, which of these are the priority market? Because frankly, we can only really meet one. And so that's another peripheral outcome of going through a compressed review timeline.

Videos

In a 2026 industry outlook interview, Raj Puri discusses how the tariffs hinder US pharma investment but drive demand for geographically segregated supply chains.

Balancing Unpredictable Tariffs with Geographically Segregated Supply Chains

In this interview, Raj Puri, chief commercial officer at Argonaut Manufacturing, discusses the complex challenges and shifting strategies within the U.S. pharmaceutical supply chain. Argonaut, a contract manufacturing organization based in Carlsbad, California, operates specialized divisions for life science diagnostics and aseptic drug product filling. Puri identifies the unexpected 2025 White House tariffs on equipment and consumables as a significant disruption for mid-sized companies attempting to expand domestic infrastructure.

Puri highlights the financial strain these policies impose, noting that Argonaut itself was hit with a seven-figure tariff on critical equipment during the final phase of a three-year investment plan. This volatility complicates long-term planning for the industry. "The tariffs have a chilling effect on companies trying to make investments into US-based pharma manufacturing facilities is simply due to their unpredictable nature," Puri explains. However, he also observes a "positive" side effect, the tariffs have driven increased interest in U.S.-based CDMOs as firms seek proactive strategies to manage their COGS.

Beyond immediate trade policy, the Puri elaborates on the broader necessity of supply chain redundancy in the wake of COVID-19 and ongoing geopolitical shake ups. Puri notes a qualitative trend where biotech and pharmaceutical companies are no longer satisfied with simply having multiple sites under one provider. Instead, they are prioritizing geographical and economic segregation to mitigate risks. Regarding this strategic shift, Puri states: "They want completely economically and geographically segregated manufacturing sites".

Ultimately, the interview underscores a critical transition period for the industry. While tariffs present a unique hurdle that hinders domestic investment, they are simultaneously accelerating a movement toward more resilient, diversified, and U.S.-centered manufacturing models.

Good morning. My name is Raj Purdy. I'm the Chief Commercial Officer at Argonaut manufacturing. Argonaut is a contract manufacturing company based in Carlsbad, California. We have two separate divisions within the company. One division is focused on the production of life science and diagnostic products, and then the second division is focused on aseptic filling of drug product. So again, pleasure to be here today.

In my opinion, the biggest and most unwelcome surprise of 2025 was the implementation of tariffs by the White House, like many other industries, pharma industry was negatively impacted by the Tariffs applied to the acquisition of new equipment and critical consumables from non-US manufacturers. Very specifically for Argonaut, we are in the final stages of implementing a three year investment plan to build a new drug product manufacturing site in Carlsbad, California. And with all the latest and greatest equipment, unexpectedly, we got hit with a seven figure tariff on one of the key pieces of equipment, which again, for a mid-sized company, is a significant challenge.

The tariffs have a chilling effect on companies trying to make investments into US-based pharma manufacturing facilities is simply due to their unpredictable nature. On the positive side though, I would say that the Tariffs applied to pharmaceutical products not made in the US have created additional interest in US based CDMOs as a potential strategy to keep down cogs. So I get I think it's being done somewhat proactively, as we don't have a lot of details on how products made by CDMOs will be treated from a tariff perspective, but we certainly are seeing increased interest as a result.

In my opinion, the issue of tariffs geopolitical shocks and global supply disruptions underscore what we already know about the importance of having redundancy and pharmaceutical supply chains, and I think covid taught us, taught that lesson as well in 2020.

While I don't have a lot of quantitative data, qualitatively, my experience has been that biotech and pharma companies are actively looking to establish secondary commercial manufacturing sites, which are both geographically and economically segregated from their primary. So we've seen that organizations are not necessarily looking to work with the same CDMO, even if they have multiple geographical sites, because if there is an issue with that organization, they're now in a difficult position. They want completely economically and geographically segregated manufacturing sites.

Nerve cell with blue background attacked by red antibodies - 3D illustration of autoimmune disease | Image Source: ©peterschreiber.media -stock.adobe.com

, a biotech company that develops programmable T cell target immune medicines, announced on Jan. 29, 2026 that it is collaborating with Eli Lilly and Company to develop tolerizing therapies that restore immune homeostasis for autoimmune diseases (1). As part of the agreement, Repertoire will receive an upfront payment of $85 million with up to an additional $1.84 billion for development and commercial milestones and tiered royalties on net sales.

Collaboration activities will be led by Repertoire until a candidate is nominated. Repertoire’s T cell receptor (TCR)-epitope discovery platform, DECODE, will be used to discover and develop the tolerizing therapy candidates. Lilly will then lead clinical development, manufacturing, regulatory affairs, and commercialization of the therapy.

“This collaboration further expands Repertoire’s partnered pipeline of tolerizing therapies and affords us the opportunity to translate the unique discoveries produced by our DECODE platform into potentially paradigm shifting new medicines for autoimmune patients by addressing the root cause of the immune dysregulation and resetting their immune system to a healthier state,” Torben Straight Nissen, PhD, chairman and CEO of Repertoire and executive partner at Flagship Pioneering, said in a press release (1). “Lilly’s established leadership in immunology and commitment to advancing novel, potentially transformative medicines to patients with clear unmet needs give us great hope for the impact our innovation can have in the hands of such an exceptional partner.”

Repertoire was founded in 2019 by Flagship Pioneering. The company’s DECODE platform reveals the entire immune synapse to provide understanding of the interactions between TCRs and their cognate antigenic epitopes. The company translates these discoveries into T cell-targeted therapies for the treatment of cancer and autoimmune diseases.

What other companies are collaborating with Flagship Pioneering and Repertoire?

In December 2025, Flagship Pioneering announced a research program in collaboration with Pfizer, in which Repertoire will identify and optimize TCR bispecifics for metastatic prostate cancer (2). Flagship’s in-house drug discovery and development unit, Pioneering Medicines, is leading the partnership with Pfizer and will drive the exploration process to discover potential drug development programs.

“Repertoire’s DECODE platform uniquely maps the entire immune synapse, presenting enormous uncharted potential to discover new antigens capable of activating the immune system to fight cancer, and when coupled with Repertoire’s immune medicine engineering technologies and capabilities, places us in a strong position to generate targeted medicines to engage them,” Nissen said in a press release at the time (2). “Guided by Pfizer’s drug development expertise in oncology, we will apply our platform to uncover new potential T-cell targeted medicines.”

“This research program with Repertoire demonstrates both the continued momentum in our strategic alliance with Pfizer and the breadth of novel modalities our Flagship companies offer as a supply chain of potential therapeutic innovation,” said Paul Biondi, Flagship Pioneering managing partner, in the press release (2). “We have now collaborated on eight programs across multiple modalities and five therapeutic areas in our shared commitment with Pfizer to co-create a pipeline of novel candidates that have a potential to become differentiated medicines with greater precision, speed, and scale for the patients who need them most.”

TCR bispecifics are a potential immunotherapy that may be able to overcome barriers associated with disease progression. The research program aims to identify and develop an early optimized TCR bispecific that can control the disease reduce toxicity, according to the company.

Repertoire Immune Medicines. Repertoire Immune Medicines Announces Strategic Collaboration with Lilly to Develop Tolerizing Therapies for Autoimmune Diseases. Press Release. Jan. 29, 2026.

Flagship Pioneering. Flagship Pioneering and Repertoire Immune Medicines Announce Agreement to Identify T Cell-Targeted Immune Medicines for Prostate Cancer Under Strategic Partnership with Pfizer. Press Release. Dec. 22, 2025.

Repertoire Immune Medicines has partnered with Eli Lilly to develop tolerizing therapies for autoimmune diseases, leveraging Repertoire's DECODE platform for T cell receptor-epitope discovery. The collaboration involves an upfront payment of $85 million to Repertoire, with potential additional payments up to $1.84 billion. Repertoire will lead initial discovery efforts, while Lilly will handle clinical development and commercialization. Additionally, Repertoire is collaborating with Pfizer to identify TCR bispecifics for metastatic prostate cancer, highlighting the potential of their DECODE platform in both autoimmune and oncology applications.

Repertoire’s T cell receptor-epitope discovery platform will be used to develop tolerizing therapy development candidates with Eli Lilly and Company.  

Repertoire Immune Medicines and Lilly Collaborate on Treatments for Autoimmune Diseases

International day of Women and Girls in science is observed every year on February 11, The day recognizes the critical role women and girls play in science and technology. 3D Rendering | Image Credit: ©Waseem Ali Khan -stock.adobe.com

 (1). This day focuses on the gender gap in science, technology, engineering, and mathematics (STEM) fields and emphasizes the need to close gender gaps in STEM through supporting girls in targeted programs and promoting actions and policies surrounding inclusion.

In recognition of the International Day of Women and Girls in Science, 

will be interviewing industry experts on the innovations and successes women have achieved in the pharmaceutical industry. We will also be highlighting some recent news about notable CEOs, scientists, and innovators impacting the industry and improving patients’ lives.

The following are some of the women we will be highlighting in the weeks to come:

Jennifer Levin Carter, MD, MPH, MBA is Founder & CEO of Medzown. Dr. Carter is a globally recognized leader in precision medicine, with a proven track record of building transformative companies at the intersection of data, technology, and patient care. Dr. Carter will be discussing lessons she’s learned from founding her own company in the biotech field. Watch Part One of our interview with Dr. Carter now, in which she discusses the differences between personalized medicine and precision medicine. Check back in February for more with Dr. Carter.


https://www.pharmtech.com/view/personalized-medicine-vs-precision-medicine

Elisabeth Gardiner, CSO of Tevard Biosciences

to explain how transfer RNA is impacting the development of gene therapies for diseases with unmet needs. In an upcoming interview, Elisabeth will discuss how women working in STEM fields uniquely contribute to areas such as rare disease treatment development.


https://www.pharmtech.com/view/gene-therapy-rare-diseases-and-transfer-rna

 to talk about her work as director of Clinical Research at 

, which is an early-phase oncology clinical trial unit located within General Hospital San Pedro in Logroño in northern Spain. Check back on February 11 to watch the interview.

, CEO of IMUNON, which is advancing a novel non-viral, DNA-based immunotherapy for women with advanced ovarian cancer and experts from Symbiosis, Quotients Sciences, and more.

 on February 11 for all of our coverage of the International Day of Women and Girls in Science.

UN. International Day of Women and Girls in Science, 11 February. UN.org. 

The International Day of Women and Girls in Science, observed on February 11, highlights the gender gap in STEM fields and promotes inclusion. PharmTech will feature interviews with industry experts, showcasing the achievements of women in the pharmaceutical industry. Notable figures include Jennifer Levin Carter, a leader in precision medicine; Elisabeth Gardiner, who discusses transfer RNA in gene therapies; and María de Miguel, who leads oncology clinical trials. The coverage aims to celebrate women's contributions to science and inspire future generations to pursue STEM careers.

Visit PharmTech.com for upcoming coverage of the International Day of Women and Girls in Science on February 11.